NCT03829449终止3 期
CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Long Term Safety and Efficacy of rVA576 (Coversin) Therapy Assessed by AEs, SAEs, Standard Lab Tests and ECG Results.
研究概览
简要总结
Long term management of patients with complement related diseases including Paroxysmal Nocturnal Haemoglobinuria and Atypical Haemolytic Uraemic Syndrome
详细描述
Patients with diseases requiring complement inhibition who have previously taken part in Akari clinical trials and who wish to continue to receive rVA576 (Coversin) after their active participation in the parent trial has completed and patients treated under compassionate use or named patient arrangements who wish to continue on rVA576 (Coversin) therapy
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients 18 years and above treated with rVA576 (Coversin) under other Akari clinical trial protocols and wish to remain on rVA576 (Coversin) at the conclusion of that trial.
- •In the opinion of the treating responsible clinician patient is receiving clinical benefit from continued treatment with study drug.
- •Evidence of sustained complement inhibition by CH50 assay. .
- •Women of childbearing potential (WOCBP) must agree to use effective contraception consistently throughout the study and have a negative pregnancy test at screening and a negative urine pregnancy test per the schedule of visits. Women cannot donate their eggs. Women are considered post-menopausal and not of childbearing potential if they have had 12 months of amenorrhea or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks previously.
- •Males with a childbearing potential partner must agree to use effective contraception consistently OR have had a vasectomy
- •Weight ≥50-100kg
- •Willing to receive appropriate prophylaxis against Neisseria meningitidis infection, by both immunisation and continuous or intermittent antibiotics
- •The patient is willing to give voluntary written informed consent
- •The patient is willing in the process of preparation and self-administration of the study drug.
排除标准
- •Patient experienced any safety event in the previous study protocol, which puts the patient at unacceptable risk in current protocol as judged by the investigator and sponsor.
- •Patient is unwilling to complete the Quality of Life instruments and diary card
- •Active meningococcal infection (section 4.3.1 for additional information)
- •Any other reason for which, in the opinion of the Investigator, it would not be in the interests of the patient to remain on rVA576 (Coversin).
- •If female, the subject is pregnant or lactating or intending to become pregnant before, during, or within 90 days after last dose; or intending to donate ova during such time period.
- •If male, the subject intends to donate sperm while on the study this study or for 90 days after last dose.
- •Failure to satisfy the Investigator of fitness to participate for any other reason or any other condition which, in the opinion of the investigator, could increase the subject's risk by participating in the study or confound the outcome of the study.
- •Use of prohibited medication
- •The subject has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse.
- •Participation in other clinical trials with investigational product.
研究组 & 干预措施
rVA576 Coversin
Experimental
The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin) for up to 4 years.
干预措施: rVA576 (Drug)
结局指标
主要结局
Long Term Safety and Efficacy of rVA576 (Coversin) Therapy Assessed by AEs, SAEs, Standard Lab Tests and ECG Results.
时间窗: On entry and every 3 months thereafter, for the duration of the study (approximately 3 years and 5 months)
To determine the safety profile of long-term rVA576 (Coversin) treatment as assessed by AEs, SAEs, Standard Lab tests and ECG results.
次要结局
- Proportion of Subjects With Thrombotic and Haemolytic Event Free Status During Each 3month Time Period Since the Start of the Study.(On entry and every 3 months thereafter, for the duration of the study (approximately 3 years and 5 months))
- Time to Thrombotic or Haemolytic Event Since Joining This Study.(Approximately 3 years and 5 months)
- Proportion of Subjects Who Require PRBC Transfusion During Each 3-month Period Since the Start of the Study and Over the Entire Period of the Study(On entry and every 3 months thereafter, for the duration of the study (approximately 3 years and 5 months))
- Time to First Transfusion Since Joining the Study.(approximately 3 years and 5 months)
- Proportion of Subjects With no Adverse Change in Overall Scores of Quality of Life Using the EORTC QLQ-C30, the EQ-5D-5L and FACIT-F Instruments at Each 3-month Time Period Since the Start of the Study.(Every 3 months up to 39 months)
- Proportion of Subjects With Serum Lactate Dehydrogenase (LDH) <1.8, >1.8 to 2.4, >2.4 to 3, and >3 Times the Upper Limit of Normal (ULN) at Each 3-month Time Period Since the Start of the Study.(12 weeks)
- Proportion of Subjects With Median Serum Lactate Dehydrogenase (LDH) <1.8, >1.8 to 2.4, >2.4 to 3, and >3 Times the Upper Limit of Normal (ULN) Over the Entire Duration of the Study.(Approximately 3 years and 5 months)
- Proportion of Transfusion-independent Subjects at Each 3-month Time Point, With Haemoglobin (g/L) Above the Baseline Haemoglobin Value They Had at the Start of the Trial From Which They Entered CONSERVE(Baseline and every 3 months up to 39 months)
- Proportion of Transfusion-independent Subjects Over the Entire Duration of the Study With Mean Haemoglobin (g/L) Above the Baseline Haemoglobin Value They Had at the Start of the Trial From Which They Entered CONSERVE(Approximately 3 years and 5 months)
- Proportion of Patients Experiencing Major Adverse Vascular Events (MAVE) Over the Entire Period of the Study.(Approximately 3 years and 5 months)
- Time to First Major Adverse Vascular Event (MAVE) for Each Subject Since Joining the Study.(Approximately 3 years and 5 months)
- Number of Major Adverse Vascular Events (MAVE) Over the Entire Period of the Study.(Approximately 3 years and 5 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
rVA576 (Coversin) Long Term Safety and Efficacy Surveillance StudyNL-OMON48556Akari Therapeutics Plc1
已完成
3 期
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic ArthritisPsoriasisNCT01519089Pfizer95
终止
2 期
An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's DiseaseCrohn's DiseaseInflammatory Bowel DiseaseNCT01009281Novartis Pharmaceuticals7
终止
2 期
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset SeizuresSeizuresNCT04686786AbbVie105
已完成
3 期
ong-term Study of ACT-541468 in patients with insomnia disorderInsomnia disorderJPRN-jRCT2080225348Idorsia Pharmaceuticals Japan Ltd.154